Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial (Journal article)
Pettitt, A. R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., . . . Hillmen, P. (2012). Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial. JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1647-1655. doi:10.1200/JCO.2011.35.9695DOI: 10.1200/JCO.2011.35.9695